Suppliers of generic, biosimilar, and value-added medicines call for reform of EU pharmaceutical laws to ensure equitable access to treatments for all patients Increased penetration
Suppliers of generic, biosimilar and value-added medicines unveil vision to enhance patient access and affordability, secure a resilient supply chain, and embed sustainable practices by 2029.
Negotiation on the new Framework Agreement on Supply and Pricing of Medicines set to be a key priority for incoming Medicines for Ireland chair and
Medicines for Ireland (MFI) are highlighting the role of inflation, rising energy and transport costs, and persistent global supply chain disruptions which have combined to create a
Medicines for Ireland (MFI) are urging Government to heed recent warnings from GPs and pharmacists nationwide on the growing risk of medicines shortages as inflation,
Medicines for Ireland (MFI) have highlighted the growing risk of medicines shortages as inflation, energy and transport costs continue to rise, and global supply chain
In line with today’s European Commission’s Guidelines on a European Gas Demand Reduction Plan1, Medicines for Europe urges Governments to maintain energy supply to medicines production sites in the event of energy restrictions in Europe.
According to findings commissioned by Medicines for Ireland (MFI) and compiled by IQVIA Ireland generic medicines now account for 57% of the volume of the total prescription market in Ireland.
Medicines for Ireland are delighted to announce the publication of the MFI, Code of Practice V2.0. Which is now available on the Medicines for Ireland
PRESS RELEASE 5 May 2022 Value Added Medicines (VAMs) are medicines based on known molecules that address healthcare needs and deliver relevant improvements for patients
We are committed to working with key stakeholders to affect real change and reforms that ensure Irish patients receive the best medical treatment in the most affordable way.
